Associated equity: Kazia Therapeutics
Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.
Kazia Therapeutics — 9 videos in collection
Kazia Therapeutics (KZIA) is an oncology-focused drug development company. Its drug candidates are designed to treat cancers which are poorly served by existing therapies.
In this video, James Garner, CEO, introduces Kazia’s expanding US management team: chief medical officer, John Friend, and chief financial officer, Karen Krumeich. John and Karen highlight their experience and what interested them about Kazia. As part of a three-episode Edison TV series, the team also discusses Kazia’s lead asset, paxalisib, a highly potent, small molecule, brain-penetrant inhibitor of PI3K/mTOR, and when we can expect final data from the ongoing Phase III study. Stay tuned for the next video, which focuses on paxalisib beyond glioblastoma.
Get access to the very latest content matched to your personal investment style.